Researchers have developed a promising new CAR T-cell therapy that precisely targets the CALR mutation, a key driver of myeloproliferative neoplasms (MPNs)—a group of rare blood cancers. Unlike current treatments that mainly control symptoms, this therapy is designed to eliminate the cancer stem cells responsible for disease progression while leaving healthy blood cells unharmed. In laboratory studies, patient samples and mouse models, the engineered immune cells successfully destroyed CALR-mutant cancer cells, even within scarred bone marrow. Researchers also found that combining the therapy with eltrombopag enhanced its cancer-killing ability in advanced disease. A Phase I clinical trial is planned, offering hope for longer-lasting remissions and potentially curative treatment for patients with CALR-mutated MPNs.
Read more at MedicalXpress